<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04871646</url>
  </required_header>
  <id_info>
    <org_study_id>A108_02CVD2105</org_study_id>
    <nct_id>NCT04871646</nct_id>
  </id_info>
  <brief_title>Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314</brief_title>
  <official_title>A Double-blind, Multi-center, Multi-regional, Randomized Controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Double-blind, Multi-center, Multi-regional, Randomized controlled, Phase 3 Clinical Trial&#xD;
      to Evaluate the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed with&#xD;
      COVID-19&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the efficacy and safety of CKD-314 by comparing the study group and control group&#xD;
      in hospitalized adult patients diagnosed with COVID-19 pneumonia&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to recovery</measure>
    <time_frame>From day1 to day 28</time_frame>
    <description>Day of recovery is defined as the first day on which the subject meets the criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to clinical improvement: Time to clinical improvement (TTCI)</measure>
    <time_frame>From day1 to day 28</time_frame>
    <description>as time (days) from randomization to a decline of 2 categories on the 8-category ordinal scale of clinical status</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">586</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>CKD-314</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with CKD-314 + SOC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD-314 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment with CKD-314 Placebo + SOC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-314+SOC</intervention_name>
    <description>CKD-314 is administered intravenously and standard of care is also performed.</description>
    <arm_group_label>CKD-314</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-314 Placebo+SOC</intervention_name>
    <description>CKD-314 placebo is administered intravenously and standard of care is also performed..</description>
    <arm_group_label>CKD-314 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged â‰¥ 18 years&#xD;
&#xD;
          2. Patients diagnosed with COVID-19 infection and pneumonia&#xD;
&#xD;
          3. Patients who have voluntarily decided to participate in the study and signed the&#xD;
             informed consent form If a patient cannot provide consent on his or her own, informed&#xD;
             consent by a legally authorized representative may be obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with history of hypersensitivity to the study drug&#xD;
&#xD;
          2. Female patients, either who are or may be pregnant or who are breastfeeding, or female&#xD;
             patients of child-bearing potential who are unable to use adequate contraception&#xD;
             during the study&#xD;
&#xD;
          3. Patients who are deemed to ineligible to participate in the study for other reasons by&#xD;
             the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hee Jin Jung, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dasom Kim</last_name>
    <phone>+82-2-3149-7993</phone>
    <email>dasom@ckdpharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hee Jin Jung</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

